预约演示

Vasomune wins FDA fast track designation for lung condition treatment

2024-05-28

临床1期临床结果快速通道临床2期

AV-001 is designed to improve lung healing in patients by providing a molecular shortcut in blood vessel growth associated with wound closure. Credits: Marko Aliaksandr/Shutterstock.com

AV-001ne Therapeutics has announced that its novel investigational medicine, AV-001, has received US Food and Drug Administration (FDA) fast track designation for the treatment of moderate to severe pathogen-induced acute respiratory distress syndrome (ARDS).

Vasomune TherapeuticsuidesAV-001 US Food and Drug Administration (FDA)pathogen-induced acute respiratory distress syndrome (ARDS)

Buyer's Guide

Top Guide for Drug Delivery Systems

Buyer's Guide

Top Guide for Cleanrooms and Cleanroom Flooring

As per the 28 May press release, fast track designation was granted based on the high unmet medical need in ARDS. The status allows for earlier interactions with the FDA in the pursuit of accelerated approval and also the possibility to undergo rolling reviews.

ARDS is a life-threatening lung injury that enables fluid to leak into the lungs, causing breathing difficulties and low blood oxygen. According to the press announcement, ARDS is characterised by high mortality rates that can reach up to 46% in patients with severe cases of the disease.

AV-001, a polyethylene glycol (PEG)-clustered Tie2 agonist peptide that was first discovered at Sunnybrook Research Institute at Sunnybrook Hospital, is designed to improve healing in patients by providing a molecular shortcut in blood vessel growth associated with wound closure.

The drug candidate is actively being evaluated in a Phase IIa study (NCT05123755) for the prevention and treARDSnt of hospitalised patients with pneumonia-associated FDAS. The primary endpoint of the study is the safety and tolerability of multiple intravenously administered doses of AV-001 compared to placebo.

ARDSAlso:MSD agrees to acqulung injuryfor up to $3bnARDS

AV-001introduces sterility testing solution foTie2arma quality controlSunnybrook Research Institute Sunnybrook Hospital

The Phase I study (NCT04737486) demonstrated a good safety and tolerability profile with strong on-target activity. There were no drug-related dipneumonia-associated ARDS no suspected unexpected severe adverse reactions (SUSARs), and no adverse events of special interest (AESIs), as rAV-001d at the 2024 Respiratory Innovation Summit (RIS).

“VasomuneMSD focused on the perEyeBiog unmet needs of people grappling with ARDS and other diseases driven by vascular endothelial instability,” said president and Chief Operating Officer of Vasomune, Dr. Brian Jahns.

The Toronto, Ontario-based biotech is not the only player in the ARDS space. In October 2023, BioAegis Therapeutics was awarded a $20m contract from the US Biomedical Advanced Research and Development Authority (BARDA) for the development of plasma gelsolin for the treatment of ARDS. Also making headway is Healios, which in April 2023, reported positive topline results from the open-label ONE-BRIDGE clinical study of somatic stem cell regenerative therapy MultiStem (HLCM051/invimestrocel) in ARDS patients across Japan.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构